Free R&D Tax Credit Analysis
Let's get started by talking to one of our R&D Tax Credit experts to see how much we can gain you by getting a FREE R&D Tax Credit analysis today!
Pharmaceutical Industry Qualifying Activities
The pharmaceutical industry is a perfect candidate for R&D tax credits, which were created to encourage American businesses to innovate; they’re now offered by the federal government and 35 states.
Pharma spends far more its revenue, by percentage, on research and development than other knowledge-based industries. The industry’s R&D expenditures increased by almost 50% between 2015 and 2019. In 2019, the average pharmaceutical company devoted almost 25% of its net revenue to research and development, net of expenses and buyer rebates. That same year, according to the Congressional Budget Office, the pharmaceutical industry directed $83 billion dollars to research and development—which, adjusted for inflation, is almost 10 times what it spent per year in the 1980s.
When deciding whether to develop a new drug, pharmaceutical companies balance the expected revenue derived from the new product; the projected cost of development; and government policies that might impact the drug’s supply and demand.
Breakdown of Qualifying Activities
R&D spending in the pharmaceutical industry tends to follow this process:
- incremental innovation
- product differentiation
- safety monitoring or clinical trials.
According to the IRS’ Pharmaceutical Industry Research Credit Audit Guidelines – Revised – 4/30/04, the pharmaceutical product development process can be broken down into four stages:
- Preclinical/Discovery Research – where new compounds are discovered.
- Clinical Development – conducted in three (3) phases.
Phase I – first trials in humans that test a compound for safety, tolerance and pharmacokinetics. The trials usually employ normal, healthy volunteers.
Phase II – pilot studies to determine efficacy and safety in selected populations of patients with the disease or condition to be treated, diagnosed, or prevented. Dose and dosing regimens are assigned for magnitude and duration of effect during this phase.
Phase III – expanded clinical trials intended to gather additional evidence of effectiveness for specific indications and to better understand safety and drug-related adverse effects.
- Regulatory Review – the New Drug Application (NDA) is submitted to a regulatory agency, such as the Food and Drug Administration, for marketing and manufacturing approval.
- Post-Marketing – activities occurring after approval to market has been granted by the appropriate regulatory agency. These activities include Phase IV studies performed to determine the incidence of adverse reactions; to determine the longterm effect of a drug; to study a patient population not previously studied; and for marketing comparisons against other products and other uses.
When deciding whether to award an R&D tax credit claim, the IRS seeks these types of documentation:
- tax work papers
- qualified wages
- qualified supplies
- qualified contract research
- tour of research facility
- organizational chart and
- job titles, grade levels, and position descriptions.
Getting an R&D Tax Credit Analysis to see if you qualify is the first step!
eBook: The Architect's Guide to R&D Tax Credits
This comprehensive e-book is designed to help you recognize which of your activities qualify for R&D tax credits!
Webinars: R&D Tax Credits
Testimonials: Our valued clients
Case Studies R&D Tax Credit
1 Year Tax Savings: $18,078 (Federal Only) Study Highlights Wages $525,358 Supplies $26,953 Rental or lease of computers 27.5-Year Contract Research $11,760 Total Qualified …
1 Year Tax Savings: $18,078 (Federal Only) Study Highlights Wages $358,407 Supplies $26,953 Rental or lease of computers 27.5-Year Contract Research $14,227 Total Qualified Research …
1 Year Tax Savings: $72,430 (Federal Only) Study Highlights Wages $1,342,919 Supplies $0 Rental or lease of computers $0 Contract Research $0 Total Qualified Research …
Top Articles: R&D Tax Credit
Future changes to the way companies can take deductions from research and development expenses may make investing in innovation more difficult, particularly for small businesses …
TAX ALERT: IRS may extend the transition period for compliance regarding research credit refund claims
IRS Update *** The IRS is extending for another year (through January 10, 2024) the transition period during which taxpayers are provided 45 days to perfect a research credit claim for refund prior to IRS’s final determination on the claim. A recent comment by an IRS official indicating that the agency may extend the … Read more
You may know that life sciences are eligible for federal research and development (R&D) tax credits nationwide—but did you know that New York State offers …